Compare Prologis Inc (PLD) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs Summit Therapeutics Inc — how do they compare? Prologis Inc trades at $135.62 (market cap $128.92B), while Summit Therapeutics Inc trades at $17.58 (market cap $13.98B). The key difference: Prologis Inc is far larger — about 9.2× Summit Therapeutics Inc's market cap, and Prologis Inc pays a 3.15% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PLD | SMMT | |
|---|---|---|
Market Cap | $128.92B | $13.98B |
Sector | Real Estate | Health |
52-Week High | $149.96 | $26.38 |
52-Week Low | $110.98 | $12.43 |
Enterprise Value | $163.66B | $13.31B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prologis (PLD) trades at $138.49, up 0.84% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue grew to $8.79B in 2025, and the company maintains high profit margins. Analyst consensus is bullish with a $160.13 price target, though technical indicators show near-term pressure with support at $137.
The outlook for PLD is positive due to consistent earnings beats and robust institutional interest, but risks include rising debt levels and market volatility. The stock offers growth potential from its real estate portfolio, yet investors should monitor debt-to-asset trends and economic conditions affecting REIT valuations.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
